Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | QDPR | P09417 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13925377 | 0.80 | NAMPT (0.47) | NAMPTACEKCNH2HRH3CCR1 | |
| SCHEMBL13515405 | 0.79 | PGK1 (0.41) | NAMPTNPC1 | |
| SCHEMBL2606198 | 0.76 | MEN1 (0.40) | NAMPTMEN1KMT2ANOTUM | |
| SCHEMBL12049583 | 0.74 | HPGD (0.40) | NAMPTACEKCNH2HRH3MEN1 | |
| SCHEMBL19981964 | 0.74 | DPP4 (0.41) | NAMPTKCNH2HRH3CCR1 | |
| SCHEMBL17888232 | 0.73 | MEN1 (0.44) | NAMPTMEN1KMT2ANOTUM | |
| SCHEMBL8261115 | 0.73 | QDPR (0.49) | NAMPTNOTUMQDPR | |
| SCHEMBL7914538 | 0.73 | BLM (0.41) | NAMPTNPC1MEN1KMT2A | |
| SCHEMBL14243055 | 0.72 | ATM (0.46) | NAMPTNPC1MEN1KMT2A | |
| SCHEMBL12049773 | 0.72 | NAMPT (0.50) | NAMPTMEN1KMT2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | RBP4 4743/4885NAMPT 517/4885ACE 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.